跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VABYSMO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VABYSMO
Authorized
STANDARD
VABYSMO
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e16b3affa393ce06
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
e16b3affa393ce06
Drug Approval Canada Name
VABYSMO
Product Name
VABYSMO
Status
Marketed
Status Date
2022-07-18
Original Market Date
2022-07-18
Din
02527618
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravitreal
Schedule
Schedule D , Prescription
Ahfs
52:92.00
Atc Original
S01LA09 FARICIMAB
Atc Name
s 01 la 09
Aig Number
0163722001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
FARICIMAB
6 MG / 0.05 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e16b3affa393ce06
Type
Standard
Back to Health Canada Approvals